Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

Stock Information for Oncocyte Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncocyte Corporation

Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
Nephros Announces Results for Quarter Ended September 30, 2023
Nephros Hires Judy Krandel as Chief Financial Officer
Nephros Schedules Third Quarter 2023 Financial Results Conference Call
Nephros to Present at LD Micro Main Event XVI
Nephros Announces Results for Quarter Ended June 30, 2023
Nephros Schedules Second Quarter 2023 Financial Results Conference Call

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.